270 related articles for article (PubMed ID: 28543134)
1. "Real life" longevity of implantable cardioverter-defibrillator devices.
Manolis AS; Maounis T; Koulouris S; Vassilikos V
Clin Cardiol; 2017 Sep; 40(9):759-764. PubMed ID: 28543134
[TBL] [Abstract][Full Text] [Related]
2. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
[TBL] [Abstract][Full Text] [Related]
3. Sex differences in implantable cardioverter-defibrillator implantation indications and outcomes: lessons from the Nationwide Israeli-ICD Registry.
Amit G; Suleiman M; Konstantino Y; Luria D; Kazatsker M; Chetboun I; Haim M; Gavrielov-Yusim N; Goldenberg I; Glikson M;
Europace; 2014 Aug; 16(8):1175-80. PubMed ID: 24554524
[TBL] [Abstract][Full Text] [Related]
4. Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators.
Alam MB; Munir MB; Rattan R; Flanigan S; Adelstein E; Jain S; Saba S
Europace; 2014 Feb; 16(2):246-51. PubMed ID: 24099864
[TBL] [Abstract][Full Text] [Related]
5. Significant Discrepancy Between Estimated and Actual Longevity in St. Jude Medical Implantable Cardioverter-Defibrillators.
Doppalapudi H; Barrios J; Cuellar J; Gannon M; Yamada T; Kumar V; Maddox WR; Plumb VJ; Brown TM; McElderry HT
J Cardiovasc Electrophysiol; 2017 May; 28(5):552-558. PubMed ID: 28181727
[TBL] [Abstract][Full Text] [Related]
6. Device Longevity in a Contemporary Cohort of ICD/CRT-D Patients Undergoing Device Replacement.
Zanon F; Martignani C; Ammendola E; Menardi E; Narducci ML; DE Filippo P; Santamaria M; Campana A; Stabile G; Potenza DR; Pastore G; Iori M; LA Rosa C; Biffi M
J Cardiovasc Electrophysiol; 2016 Jul; 27(7):840-5. PubMed ID: 27094359
[TBL] [Abstract][Full Text] [Related]
7. Association of cardiac resynchronization therapy with the incidence of appropriate implantable cardiac defibrillator therapies in ischaemic and non-ischaemic cardiomyopathy.
Loughlin G; Avila P; Martinez-Ferrer JB; Alzueta J; Vinolas X; Brugada J; Arizon JM; Fernandez-Lozano I; García-Campo E; Basterra N; Fernandez De La Concha J; Arenal A
Europace; 2017 Nov; 19(11):1818-1825. PubMed ID: 28339565
[TBL] [Abstract][Full Text] [Related]
8. The Occurrence of Implantable Cardioverter Defibrillator Therapies After Generator Replacement in Patients Who No Longer Meet Primary Prevention Indications.
Kawata H; Hirai T; Doukas D; Hirai R; Steinbrunner J; Wilson J; Noda T; Hsu J; Krummen D; Feld G; Wilber D; Santucci P; Birgersdotter-Green U
J Cardiovasc Electrophysiol; 2016 Jun; 27(6):724-9. PubMed ID: 26915696
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
[TBL] [Abstract][Full Text] [Related]
10. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
[TBL] [Abstract][Full Text] [Related]
11. Incremental benefit of cardiac resynchronisation therapy with versus without a defibrillator.
Martens P; Verbrugge FH; Nijst P; Dupont M; Nuyens D; Herendael HV; Rivero-Ayerza M; Tang WH; Mullens W
Heart; 2017 Dec; 103(24):1977-1984. PubMed ID: 28716973
[TBL] [Abstract][Full Text] [Related]
12. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy.
Thavikulwat AC; Tomson TT; Knight BP; Bonow RO; Choudhury L
J Cardiovasc Electrophysiol; 2016 Aug; 27(8):953-60. PubMed ID: 27138377
[TBL] [Abstract][Full Text] [Related]
13. Low Prevalence of Inappropriate Shocks in Patients With Inherited Arrhythmia Syndromes With the Subcutaneous Implantable Defibrillator Single Center Experience and Long-Term Follow-Up.
Rudic B; Tülümen E; Berlin V; Röger S; Stach K; Liebe V; El-Battrawy I; Dösch C; Papavassiliu T; Akin I; Borggrefe M; Kuschyk J
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042423
[TBL] [Abstract][Full Text] [Related]
14. Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Défibrillateur Automatique Implantable-Prévention Primaire registry.
Defaye P; Boveda S; Klug D; Beganton F; Piot O; Narayanan K; Périer MC; Gras D; Fauchier L; Bordachar P; Algalarrondo V; Babuty D; Deharo JC; Leclercq C; Marijon E; Sadoul N;
Europace; 2017 Sep; 19(9):1478-1484. PubMed ID: 28340096
[TBL] [Abstract][Full Text] [Related]
15. Battery longevity from cardiac resynchronization therapy defibrillators: differences between manufacturers and discrepancies with published product performance reports.
Alam MB; Munir MB; Rattan R; Adelstein E; Jain S; Saba S
Europace; 2017 Mar; 19(3):421-424. PubMed ID: 27009183
[TBL] [Abstract][Full Text] [Related]
16. Battery drain in daily practice and medium-term projections on longevity of cardioverter-defibrillators: an analysis from a remote monitoring database.
Boriani G; Ritter P; Biffi M; Ziacchi M; Diemberger I; Martignani C; Valzania C; Valsecchi S; Padeletti L; Gadler F
Europace; 2016 Sep; 18(9):1366-73. PubMed ID: 26847076
[TBL] [Abstract][Full Text] [Related]
17. Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry.
Providência R; Marijon E; Lambiase PD; Bouzeman A; Defaye P; Klug D; Amet D; Perier MC; Gras D; Algalarrondo V; Deharo JC; Leclercq C; Fauchier L; Babuty D; Bordachar P; Sadoul N; Piot O; Boveda S
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873687
[TBL] [Abstract][Full Text] [Related]
18. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
[TBL] [Abstract][Full Text] [Related]
19. Battery longevity of implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators: technical, clinical and economic aspects. An expert review paper from EHRA.
Boriani G; Merino J; Wright DJ; Gadler F; Schaer B; Landolina M
Europace; 2018 Dec; 20(12):1882-1897. PubMed ID: 29757390
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
